Although an association between prognosis and lobar location of lung cancer, particularly the left lower lobe (LLL), has been suggested, the certainty of such association remains controversial. The purpose of this study was to evaluate the impact of tumour lobar location on surgical outcomes as an independent prognostic factor for survival in our non-small cell lung cancer (NSCLC) patient series.
INTRODUCTION
Lung cancer is the leading cause of cancer mortality in the world, and non-small cell lung cancer (NSCLC) comprises the majority of lung cancers. Complete resection, whenever feasible, is generally recognized as the most effective initial treatment for NSCLC. However, even with complete resection, the 5-year survival rates are disappointing and range from 79.4-83.9% for stage IA to 29. .8% for stage IIIA [1] [2] [3] .
Lower lobe tumours have been reported to be associated with poorer survival than upper lobe tumours [4] . On the other hand, it has also been contended that tumour location within the lungs does not independently predict survival [5] . Thus, whether the location of a tumour in the lungs is a prognostic factor remains controversial.
The purpose of this study was to evaluate the impact of tumour lobar location as an independent prognostic factor for survival in a long series of NSCLC patients at our institution.
MATERIALS AND METHODS
From January 2000 to December 2007, a total of 1145 patients underwent complete resection of NSCLC at our hospital. We excluded 167 patients who had received preoperative chemotherapy, radiotherapy or both, or who had been given a diagnosis of low-grade malignant histologies, including carcinoid, mucoepidermoid carcinoma and adenoid cystic carcinoma. The remaining 978 patients were enrolled in this study. We defined complete resection as lobectomy or more extensive lung resection with systemic ipsilateral hilar and mediastinal lymph node dissection and no evidence of residual cancer either macroscopically or microscopically. The median follow-up period was 3.8 years. The Institutional Review Board of our hospital approved the data collection and analyses, and waived the need to obtain written informed consent from each patient since all data were retrospective.
We reviewed the medical records of each patient for clinicopathological information including age, gender, pathological nodal involvement, vessel invasion (vascular invasion and lymphatic permeation), pleural invasion (as defined in the 7th Edition of the TNM Classification for Lung and Pleural Tumors), tumour location and histologic type. Disease stages were based on the 7th Edition of the TNM Classification for Lung and Pleural Tumors of the Union for International Cancer Control. The histologic type was determined according to the 3rd Edition of the World Health Organization Classification. We used haematoxylin-eosin and Elastica van Gieson stains for the evaluation of vessel and pleural invasion.
Overall survival (OS) was estimated using the Kaplan-Meier method, and differences in survival were determined by log-rank analysis. Zero time was the date of pulmonary resection, and the end point was defined as the date of death from any cause. The last follow-up observation was censored when the patient was alive or lost to follow-up. All P-values were twosided and P-values <0.05 were considered a statistically significant difference. Univariate analysis was conducted among the different groups.
Categorical variables were analysed using the χ 2 -test. Differences between two groups were tested using Student's t-test. Multivariate analysis was performed using the Cox proportional hazards model to examine the association between survival and potential prognostic factors. A probability value of <0.05 was considered statistically significant. All statistical calculations were performed using SPSS for Windows version 15.0 (SPSS, Inc., Chicago, IL, USA).
RESULTS
The characteristics of the patients are shown in Table 1 . The 978 patients in this study consisted of 574 men (58.7%) and 404 women (41.3%). The mean age was 65.0 years (range: 22-86). Among the 978 patients, the tumours in 143 (14.6%) patients were located in the LLL. The 143 patients with LLL tumours had a lower proportion of adenocarcinoma than the 835 patients with non-LLL tumours, and there were significant differences in histology (adenocarcinoma vs non-adenocarcinoma) between LLL and non-LLL tumours (P = 0.02). Tumour size was significantly larger in LLL tumours than in non-LLL tumours (mean: 3.4 and 2.9 cm, respectively; P = 0.0001). However, there was no significant difference between LLL and non-LLL tumours with regard to the several clinical factors including sex, age, operation procedure, pT factor, pN factor, p-Stage, vascular invasion, lymphatic permeation and pleural invasion.
The 5-year OS rates in patients whose NSCLC were located in the LLL and other lobes (non-LLL) were 73.1 and 74.3%, respectively (P = 0.86) (Fig. 1A) . In 768 patients without lymph node metastasis, the 5-year OS rates for LLL (n = 110) and non-LLL (n = 658) tumours were 86.1 and 78.8%, respectively, with no significant difference (P = 0.07) (Fig. 1B) . However, in 210 patients with lymph node metastasis, the 5-year OS rates for LLL (n = 33) and non-LLL (n = 177) tumours were 32.7 and 57.7%, respectively, showing a significant association between survival rates and tumour lobe location in NSCLC patients with nodal metastasis (P = 0.01) (Fig. 1C) . Notably, although the 5-year OS rate of N1 patients with non-LLL (74.2%) was significantly higher than that of N1 patients with LLL (33.6%) (P = 0.0007), there was no significant difference in the 5-year OS rate between N2 patients with LLL (39.0%) and N2 patients with non-LLL (36.9%) (P = 0.42) (data not shown). Moreover, we divided all cases into four groups [right upper lobe (RUL), right middle or lower lobe (RMLL), left upper lobe (LUL) and left lower lobe (LLL)] according to tumour locations, and performed analysis for survival. In patients with lymph node metastasis, the 5-year OS rates for RUL (n = 54), RMLL (n = 65), LUL (n = 58) and LLL (n = 33) were 60.6, 60.8, 52.1 and 32.7%, respectively (Fig. 1D ). There was a statistically significant difference in the 5-year OS rate between LLL and RUL, or RMLL (P = 0.03 and 0.03, respectively), but while the 5-year OS rate for LLL was worse than that of LUL there was no statistically significant difference (P = 0.056). On the other hand, in patients without lymph node metastasis, the 5-year OS rates for RUL (n = 286), RMLL (n = 216), LUL (n = 156) and LLL (n = 110) were 78.0, 78.5, 80.6 and 86.1%, respectively. There was no significant difference in the 5-year OS rates among LLL and RUL, RMLL, or LUL (P = 0.16, respectively) (data not shown).
We conducted a more detailed analysis on the 210 patients with lymph node metastasis to clarify the association of various prognostic factors with survival rate. Univariate analysis showed that a tumour size of >3 cm (P = 0.01), N2 (P < 0.0001), the presence of pleural invasion (P = 0.006) and LLL tumour (P = 0.01) were risk factors significantly associated with survival (Table 2) . Multivariate analysis using the Cox regression model demonstrated that LLL tumour [hazard ratio (HR) = 1.84, 95% confidence interval (CI): 1.12-3.05, P = 0.02], a tumour size of >3 cm (HR = 1.68, 95% CI: 1.08-2.63, P = 0.02) and N status (HR = 2.28, 95% CI: 1.47-3.54, P < 0.001) were significant independent predictors for survival (Table 3 ). 
DISCUSSION
The TNM stage classification was developed to provide high specificity for patients with a similar prognosis and treatment options. There are several recent reports of poor prognostic factors in lung cancer [6, 7] . In the TNM classification, the location of the primary tumour does not affect prognosis. However, several studies of prognostic factors in resected NSCLC showed that lower lobe lesions increase mortality.
Lower lobe tumours were previously shown to be associated with worse-term survival than upper lobe tumours [4] . Moreover, death within 5 years is caused more frequently by lower lobe tumours than by upper lobe tumours, the difference between the right and left lungs being largely due to the low survival rate associated with tumours of the LLL [8] . A previous study has shown that differences in survival rates are associated with lobar location, such that patients with upper lobe tumours showed better long-term survival than patients with middle lobe or lower lobe tumours [9] . Recent studies have shown that tumours located in non-upper lobes such as the right middle lobe (RML), right lower lobe (RLL) and LLL independently had an increased risk of mortality in patients with stage IB NSCLC compared with tumours located in the upper lobes [10] . Similarly, multivariate analysis of patients undergoing surgery for T2 tumours previously showed that patients with LLL tumours had significantly worse survival outcomes than those who had tumours in other lobar locations [11] . Rocha et al. [12] found that the presence of the primary tumour in the lower lobe was the only statistically significant factor associated with upstaging, and other factors such as patient age, smoking history, weight loss, tumour size and tumour histology were not associated with upstaging.
In our NSCLC patient series, the OS curves between LLL and non-LLL patients were similar for all patients, and no significant difference was observed (P = 0.86). However, in patients with lymph node metastasis, the 5-year OS rates of LLL and non-LLL patients were 32.7 and 57.7%, respectively, showing a significant difference between the two categories (P = 0.01). Moreover, according to the analysis between the four groups of tumour locations in patients with lymph node metastasis, LLL tumours had significantly worst survival, with only a slight difference between LLL and LUL (P = 0.056). When we subdivided the N category into pN1 and pN2 subgroups, the survival rate of LLL patients was significantly different from that of non-LLL patients for pN1 (P < 0.001), but not for pN2 (P = 0.42). Moreover, the 5-year OS of 33.6% in LLL patients with N1 was lower than that of 39.0% in LLL with N2, but there was no statistically significant difference (P = 0.39) (data not shown). In the N1 patients, there was no significant difference in the number of metastatic lymph node, in the pattern of recurrence (locoregional or distant), or in the cause of death between LLL and non-LLL groups (data not shown). We have not fully clarified the underlying reasons for this finding but we speculate that the lack of statistical significance may be, in part, due to the small number of LLL patients with pN2 (n = 11). These results suggest that the unfavourable prognosis of lower lobe lesions is affected by the presence or absence of lymph node metastasis. In particular, this study showed that tumour size (P = 0.01), N status (P < 0.0001), pleural invasion (P < 0.01) and tumour location (P = 0.01) accounted for significant differences between the OS curves of patients with lymph node metastasis. On multivariate analysis, LLL tumour with lymph node metastasis was shown to be an independent prognostic factor for OS, as well as tumour size and N status (HR = 1.84, 95% CI: 1.12-3.05, P = 0.02).
Right lung cancer spreads mainly to mediastinal ipsilateral nodes. In left lung cancer, contralateral and ipsilateral lymphatic spread occurs with the same frequency on each side [8] . The lymphatic drainage of the lungs to the mediastinal lymph nodes has been studied extensively. Various techniques of injection of dyes into the lymphatic channels of lungs from autopsy specimens of stillborn infants and adults without pulmonary disease have been used by Rouvière [13] . Notably, the dynamic study using lymphoscintigraphy in normal healthy subjects and the lymphatic drainage routes described by Hata et al. [14] are generally in agreement with the patterns described by Nohl-Oser [15] . Drainage from the basal segments of the RLL rarely distributed to the left side of the mediastinum. In contrast, contralateral mediastinal drainage from the left lung is relatively common, occurring most frequently through the subcarinal nodes, as initially pointed out by Rouvière [11] and reconfirmed by all subsequent studies. Occasionally, crossover occurs through the lower paratracheal nodes in drainage from the LLL. Nohl-Oser [15] previously reported that the metastasis rate to the right upper paratracheal nodes was 22% for LUL cancer and 40% for LLL cancer, and the incidence rate of contralateral metastases from tumours in the RLL in metastatic mediastinal node disease was 7%. Left hilar lymphatics connect to left tracheobronchial nodes or right paratracheal nodes via subcarinal nodes. Therefore, LLL tumours may tend to spread to contralateral mediastinal lymph nodes. Although Toker et al. [16] reported that dissection of the contralateral paratracheal lymph nodes is possible without undertaking more extensive surgical dissection, including cervical dissection techniques, in our NSCLC patient series, we performed systematic mediastinal lymph node dissection, defined as the en-bloc removal of all ipsilateral lymph nodes along with the surrounding fat tissue. Since we did not perform contralateral mediastinal lymph node dissection, we could not accurately evaluate the involvement of contralateral mediastinal lymph nodes in patients with no CT evidence of contralateral lymph nodes. Patients with LLL tumours with lymph node metastasis may include N3 patients who have contralateral mediastinal lymph node metastasis, despite no evidence of contralateral lymphadenopathy on preoperative CT film. In such cases, the majority of first recurrences may be locoregional. In our patient series, however, the first recurrence was more frequently distant recurrence than locoregional recurrence in both LLL and non-LLL tumours, and there were no significant differences in recurrence rates between LLL and non-LLL tumours (data not shown). Distant recurrence is easier to assess clinically and radiographically than locoregional recurrence, and thus the rate of locoregional recurrence can be underreported. Lymph node metastasis promoted a higher incidence of distant recurrence rather than local recurrence [17] .
Moreover, tumour size was significantly larger in LLL tumours than in non-LLL tumours (P = 0.0001). These patients with LLL tumours had worse survival outcomes, possibly due to the LLL tumours being hidden by the shadow of the left heart, which made them difficult to find.
A summary of studies [5, [8] [9] [10] [11] [18] [19] [20] showing the association between tumour location and prognosis is shown in Table 4 . Regardless of LLL tumours, most studies, except the study of Ou et al. [8] , indicate that in the advanced stage, tumour location affects the prognosis, Puri et al. [5] showed no relationship between tumour location and prognosis in the early stage and Inoue et al. [19] reported that tumour location does not affect prognosis in N0 or N1 tumours. Based on our present results, we speculate that tumour location is less likely to affect survival in early-stage tumours, but the prognosis may be affected by tumour location in advanced stage tumours. We, therefore, conclude that LLL tumours have worse outcomes in lymph nodepositive NSCLC.
The limitations of this study include its retrospective nature, which evaluated cases from 2000, a small sample size, and the fact that routine adjuvant chemotherapy for N1 or higher patients was started in 2004. These limitations complicated the evaluation of the effects of tumour location on prognosis with respect to adjuvant chemotherapy.
In conclusion, LLL tumours were found to be strongly associated with mortality in NSCLC patients with lymph node metastasis. The location of the primary tumour may aid in determining the optimal management strategy and allow for more accurate prediction of prognosis. This may affect staging criteria and further studies are needed to clarify the underlying reasons why LLL tumours with lymph node metastasis have unfavourable prognoses. 
